HC Wainwright Reiterates “Buy” Rating for Rani Therapeutics (NASDAQ:RANI)

Rani Therapeutics (NASDAQ:RANI)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a note issued to investors on Friday,Benzinga reports. They presently have a $11.00 price target on the stock. HC Wainwright also issued estimates for Rani Therapeutics’ Q1 2026 earnings at ($0.06) EPS, Q2 2026 earnings at ($0.07) EPS, Q3 2026 earnings at ($0.07) EPS, Q4 2026 earnings at ($0.07) EPS and FY2030 earnings at ($0.30) EPS.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Rani Therapeutics in a research note on Monday, December 29th. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $8.33.

Rani Therapeutics Price Performance

NASDAQ:RANI opened at $0.81 on Friday. The company has a market capitalization of $98.50 million, a price-to-earnings ratio of -1.37 and a beta of 0.39. The business has a 50 day moving average of $1.27 and a 200 day moving average of $1.31. Rani Therapeutics has a 1-year low of $0.39 and a 1-year high of $3.87.

Rani Therapeutics (NASDAQ:RANI) last issued its quarterly earnings results on Thursday, March 26th. The company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.04). The business had revenue of $1.46 million for the quarter, compared to analyst estimates of $5.00 million. As a group, sell-side analysts anticipate that Rani Therapeutics will post -1.01 EPS for the current year.

Hedge Funds Weigh In On Rani Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of RANI. Jefferies Financial Group Inc. purchased a new position in Rani Therapeutics in the 4th quarter worth approximately $40,000. Virtu Financial LLC purchased a new stake in shares of Rani Therapeutics during the fourth quarter valued at approximately $69,000. CWA Asset Management Group LLC grew its holdings in shares of Rani Therapeutics by 80.0% in the third quarter. CWA Asset Management Group LLC now owns 150,000 shares of the company’s stock worth $75,000 after purchasing an additional 66,667 shares during the last quarter. OMERS ADMINISTRATION Corp purchased a new position in shares of Rani Therapeutics in the fourth quarter worth $93,000. Finally, Farallon Capital Management LLC purchased a new position in shares of Rani Therapeutics in the fourth quarter worth $105,000. 30.19% of the stock is currently owned by institutional investors.

Rani Therapeutics Company Profile

Rani Therapeutics is a clinical-stage biopharmaceutical company developing oral delivery technologies for large-molecule drugs. The company’s proprietary RaniPill platform is designed to enable the gastrointestinal delivery of biologic therapies traditionally administered via injection. Through a swallowable capsule that autonomously deploys a microscopic injector in the small intestine, Rani aims to improve patient convenience and adherence for peptide and protein therapies, including insulin and other hormones.

Since its founding in 2012, Rani Therapeutics has advanced its lead programs through early-phase clinical trials, demonstrating proof-of-concept for oral insulin delivery.